Albany, NY -- (SBWIRE) -- 09/16/2019 -- Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast-2028
1. Ankylosing Spondylitis is found to be more prevalent in men as compared to women, with around 358,880 male and 146,585 female cases in 2017 in the United States.
2. There were 1,389,116 Ankylosing Spondylitis prevalent cases in 2017 in the 7MM.
3. Germany had the highest Ankylosing Spondylitis prevalent population, followed by Italy with around 192,013 cases in 2017.
DelveInsight launched a new report on Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Ankylosing Spondylitis market report covers a descriptive overview and comprehensive insight of the Ankylosing Spondylitis epidemiology and Ankylosing Spondylitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Ankylosing Spondylitis market report provides insights on the current and emerging therapies.
3. Ankylosing Spondylitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Ankylosing Spondylitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ankylosing Spondylitis market.
Request for sample pages
"The United States ranked highest for Ankylosing Spondylitis diagnosed population among the 7MM countries."
Ankylosing Spondylitis Market analysis carried out for the period of 2017-2028 demonstrates that the Ankylosing Spondylitis market size was found out to be USD 3240.7 million in 2017 in 7MM. The United States accounts for the largest Ankylosing Spondylitis market size in 7MM, in comparison to the EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest Ankylosing Spondylitis market size worth USD 666.87 million in 2017, while Spain had the lowest Ankylosing Spondylitis market size valued at USD 108.87 million in 2017.
Currently, the cure is not available in the Ankylosing Spondylitis market and the available therapies mainly help to reduce the discomfort, pain and inflammation caused by Ankylosing Spondylitis. In terms of molecule type, the Ankylosing Spondylitis market can be segregated into small molecules, biologics, and bio-similars.
At present, the therapeutic Ankylosing Spondylitis market size is mainly accounted by Physical therapy, Surgery, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs-ibuprofen and naproxen), Steroids (corticosteroids), Disease-Modifying Anti-Rheumatic Drugs (DMARDs- methotrexate), and biologics.
Various biosimilars of Adalimumab, Remicade and Etanercept have now been approved by FDA and EMA, with Remsima/Inflectra, being the first biosimilar approved in Europe in 2013, Japan in 2014 and in the US in 2017.
The total Ankylosing Spondylitis market is calculated based on characterization of the current Ankylosing Spondylitis into 4 segments: current therapy (conventional therapies and biologics), current biosimilars (Remisima/Inflectra), emerging biosimilars (GP2017 and YLB-113) and emerging therapies (Ixekizumab, tofacitinib, bimekizumab). The dynamics of Ankylosing Spondylitis market is anticipated to change owing to the expected launch of emerging therapies and biosimilars during the forecasted period (2019-2028).
The launch of the emerging therapies is expected to significantly impact Ankylosing Spondylitis treatment scenario in the upcoming years:-
Drugs covered
1. Ixekizumab
2. Tofacitinib
3. Bimekizumab
4. Filgotinib
5. Tildrakizumab
6. Upadacitinib
7. KHK4827
And many others
The key players in Ankylosing Spondylitis market are:
1. Eli Lillyand Co.
2. Pfizer
3. UCB Biopharma
4. Galapagos NV
5. Abbvie
6. Kyowa Kirin
7. Sun Pharmaceuticals/Merck and Co
And many others
Table of contents
1. Key Insights
2. Ankylosing Spondylitis Market Overview at a Glance
3. Ankylosing Spondylitis Disease Overview
4. Ankylosing Spondylitis Epidemiology and Patient Population
5. Country Wise Ankylosing Spondylitis Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Ankylosing Spondylitis Current Treatment Practices
7. Unmet Needs
8. Ankylosing Spondylitis Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Key cross competition- Approved Biosimilars
8.3. Cimzia: UCB Inc.
8.4. Humira: AbbVie
8.5. Celebrex: Pfizer
8.6. Enbrel: Amgen/Pfizer
8.7. Remicade: Janssen Biotech
8.8. Simponi: Janssen Biotech
8.9. Vimovo: Pozen
8.10. Cosentyx: Novartis
8.11. Arcoxia: Merck
8.12. Indocin: Iroko Pharmaceuticals
8.12.4. Naprelan: Syntex Pharmaceuticals
8.13. Rayos: Horizon Pharma
9. Ankylosing Spondylitis Emerging Therapies
9.3. Ixekizumab: Eli Lilly and Co.
9.4. Tofacitinib: Pfizer
9.5. KHK4827: Kyowa Kirin
9.6. Bimekizumab: UCB Biopharma
9.7. Filgotinib: Galapagos NV
9.8. Upadacitinib: Abbvie
10. Ankylosing Spondylitis: 7 Major Market Analysis
11. Ankylosing Spondylitis Market Outlook by Country
11.1. The United States: Market Outlook
11.2. United States Market Size
11.3. EU-5 Countries: Market Outlook
11.4. Germany
11.5. France
11.6. Italy
11.7. Spain
11.8. United Kingdom
11.9. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight